How Is Mounjaro Different from Ozempic: The Receptor, Dose, and Efficacy Breakdown That Actually Matters

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) activates both GLP-1 and GIP receptors; Ozempic (semaglutide) activates only GLP-1, making Mounjaro a dual agonist with different metabolic effects
• Mounjaro produces 15-21% total body weight loss in obesity trials vs 10-15% for Ozempic at comparable treatment durations
• Mounjaro's maximum dose is 15 mg weekly; Ozempic's is 2 mg weekly (different molecules, not directly comparable by weight)
• Both cause nausea and delayed gastric emptying, but Mounjaro shows slightly higher nausea rates during titration and Ozempic shows slightly higher injection site reactions

Direct answer (40-60 words)

Mounjaro contains tirzepatide, a dual GLP-1 and GIP receptor agonist. Ozempic contains semaglutide, a GLP-1 receptor agonist only. The GIP receptor activation in Mounjaro enhances insulin secretion and fat metabolism differently than GLP-1 alone, producing greater weight loss in head-to-head trials but similar glycemic control. Both slow gastric emptying and reduce appetite through GLP-1 pathways.

Table of contents

1. The single-receptor vs dual-receptor difference
2. What the GIP receptor actually does (and why it matters)
3. Head-to-head efficacy: weight loss and A1C reduction compared
4. Dosing schedules and titration protocols
5. Side effect profiles: where they overlap and where they diverge
6. Cost comparison: brand vs compounded versions
7. What most articles get wrong about "Mounjaro is stronger"
8. The decision framework: which medication fits which patient
9. FDA approval differences and off-label use
10. When switching from one to the other makes sense
11. The FormBlends clinical pattern: who stays on which medication
12. FAQ
13. Sources

The single-receptor vs dual-receptor difference

Ozempic's active ingredient, semaglutide, is a GLP-1 receptor agonist. It binds to and activates the GLP-1 receptor on pancreatic beta cells, in the brain, and in the GI tract. This triggers insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite through hypothalamic pathways.

Mounjaro's active ingredient, tirzepatide, is a dual GLP-1 and GIP receptor agonist. It does everything semaglutide does at the GLP-1 receptor, plus it activates the GIP (glucose-dependent insulinotropic polypeptide) receptor.

The GIP receptor is expressed on pancreatic beta cells, adipocytes (fat cells), bone cells, and in the central nervous system. When activated, it:

• Enhances glucose-dependent insulin secretion (same as GLP-1 but through a different signaling pathway)
• Promotes lipid uptake into adipocytes and shifts fat storage from visceral to subcutaneous depots
• May enhance GLP-1 receptor signaling through receptor crosstalk (the two receptors potentiate each other when co-activated)
• Reduces inflammation in adipose tissue

The net effect is that tirzepatide produces greater weight loss than semaglutide at comparable GLP-1 receptor activation levels. The GIP component appears to add metabolic benefit beyond what GLP-1 alone provides.

This is not a "Mounjaro is twice as strong" story. The two drugs work through overlapping but distinct mechanisms. The dual-receptor activation is why tirzepatide consistently outperforms semaglutide in weight-loss endpoints in published trials.

What the GIP receptor actually does (and why it matters)

GIP was historically called "gastric inhibitory polypeptide" because early researchers thought it inhibited gastric acid. That name turned out to be wrong. GIP actually stimulates insulin secretion in response to food, especially fat and carbohydrate.

For decades, GIP was considered a less important incretin than GLP-1 because GIP receptor signaling is blunted in people with type 2 diabetes. The assumption was that activating a receptor that doesn't work well in diabetic patients would be pointless.

Tirzepatide's development challenged that assumption. When you activate both GLP-1 and GIP receptors together, the GIP signal appears to restore function. The leading hypothesis is that GLP-1 receptor activation sensitizes the GIP receptor, and vice versa, through intracellular signaling crosstalk (Frias et al., Lancet 2021).

The GIP receptor's role in adipocytes is where the weight-loss difference likely comes from. GIP promotes the shift of fat from visceral (around organs, metabolically harmful) to subcutaneous (under skin, metabolically neutral) depots. It also increases energy expenditure in brown adipose tissue in animal models, though this effect is harder to measure in humans.

In the SURPASS-2 trial, tirzepatide 15 mg produced 12.4 kg (27.3 lb) weight loss vs semaglutide 1 mg's 6.2 kg (13.7 lb) over 40 weeks in patients with type 2 diabetes (Frías et al., NEJM 2021). The semaglutide dose in that trial was the diabetes dose, not the obesity dose, but the signal is clear: dual agonism produces more weight loss.

Head-to-head efficacy: weight loss and A1C reduction compared

The table below compares the two drugs in their respective obesity trials and in the only head-to-head diabetes trial (SURPASS-2).

Study	Drug	Dose	Duration	Weight loss (mean)	A1C reduction (mean)	Population
STEP 1 (semaglutide)	Semaglutide	2.4 mg weekly	68 weeks	14.9%	1.6% (diabetic subgroup)	Obesity without diabetes (N=1,961)
SURMOUNT-1 (tirzepatide)	Tirzepatide	15 mg weekly	72 weeks	20.9%	Not primary endpoint	Obesity without diabetes (N=2,539)
SURMOUNT-1	Tirzepatide	10 mg weekly	72 weeks	19.5%	Not primary endpoint	Obesity without diabetes
SURPASS-2 (head-to-head)	Tirzepatide	15 mg weekly	40 weeks	11.2 kg (24.7 lb)	2.46%	Type 2 diabetes (N=1,879)
SURPASS-2	Semaglutide	1 mg weekly	40 weeks	5.7 kg (12.6 lb)	1.86%	Type 2 diabetes
STEP 2 (semaglutide, diabetes)	Semaglutide	2.4 mg weekly	68 weeks	9.6%	1.6%	Type 2 diabetes (N=1,210)

The SURPASS-2 trial is the only direct head-to-head comparison, but it used semaglutide 1 mg (the diabetes dose) rather than 2.4 mg (the obesity dose). Even at the lower semaglutide dose, tirzepatide 15 mg produced nearly double the weight loss.

Extrapolating across trials (always imperfect), tirzepatide 15 mg appears to produce 5 to 7 percentage points more total body weight loss than semaglutide 2.4 mg over 68 to 72 weeks. Both drugs produce clinically meaningful A1C reductions in diabetic patients, with tirzepatide showing a modest advantage (0.4 to 0.6% greater A1C reduction).

The weight-loss difference is the more striking signal. A patient starting at 250 lb would lose roughly 37 lb on semaglutide 2.4 mg vs 52 lb on tirzepatide 15 mg, based on trial averages. Individual variation is wide, but the population-level difference is consistent across trials.

Dosing schedules and titration protocols

Both drugs are injected subcutaneously once weekly. The titration schedules differ.

Ozempic (semaglutide) titration for diabetes:

• Start: 0.25 mg weekly for 4 weeks
• Escalate to 0.5 mg weekly (maintenance dose for many patients)
• Optional escalation to 1 mg weekly after 4+ weeks at 0.5 mg
• Maximum: 2 mg weekly (approved 2022)

Wegovy (semaglutide) titration for obesity:

• Start: 0.25 mg weekly for 4 weeks
• 0.5 mg weekly for 4 weeks
• 1 mg weekly for 4 weeks
• 1.7 mg weekly for 4 weeks
• Maintenance: 2.4 mg weekly

Mounjaro (tirzepatide) titration for diabetes:

• Start: 2.5 mg weekly for 4 weeks
• Escalate to 5 mg weekly
• Optional escalation by 2.5 mg increments every 4 weeks
• Maximum: 15 mg weekly

Zepbound (tirzepatide) titration for obesity:

• Start: 2.5 mg weekly for 4 weeks
• Escalate to 5 mg weekly for 4 weeks
• Optional escalation to 7.5 mg, 10 mg, 12.5 mg, or 15 mg in 4-week intervals
• Maximum: 15 mg weekly

The starting doses are not comparable by weight. Semaglutide 0.25 mg and tirzepatide 2.5 mg are both sub-therapeutic starter doses designed to minimize nausea during the adaptation phase. The receptor binding profiles and half-lives differ, so milligram-to-milligram comparisons are meaningless.

Both drugs have roughly 7-day half-lives, which is why once-weekly dosing works. Missing a dose by a day or two has minimal impact on steady-state levels.

Side effect profiles: where they overlap and where they diverge

The GI side effects overlap almost completely because both drugs slow gastric emptying through the GLP-1 receptor.

Side effect	Semaglutide 2.4 mg (STEP 1)	Tirzepatide 15 mg (SURMOUNT-1)	Placebo (pooled)
Nausea	44.2%	31.7%	12.6%
Diarrhea	31.5%	23.0%	15.8%
Vomiting	24.8%	12.2%	4.3%
Constipation	23.4%	16.8%	11.2%
Abdominal pain	19.6%	11.7%	9.4%
GERD/reflux	5.7%	9.4%	3.8%
Injection site reaction	6.8%	3.1%	2.2%

Semaglutide shows higher nausea and vomiting rates. Tirzepatide shows slightly higher reflux rates. The reflux difference likely relates to the GIP receptor's effects on gastric motility, though the mechanism isn't fully understood.

Both drugs carry the same black-box warning for thyroid C-cell tumors (based on rodent studies, not observed in human trials). Both are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Both drugs increase heart rate modestly (2 to 4 bpm on average) and carry a small risk of pancreatitis (0.2 to 0.4% in trials) and gallbladder disease (1.5 to 2.5% in trials, mostly during rapid weight loss).

The discontinuation rate due to adverse events was 6.2% for semaglutide 2.4 mg in STEP 1 and 6.1% for tirzepatide 15 mg in SURMOUNT-1. Essentially identical tolerability at the population level.

Cost comparison: brand vs compounded versions

Brand-name pricing (as of April 2026, without insurance):

• Ozempic: $950 to $1,050 per month
• Wegovy: $1,350 to $1,450 per month
• Mounjaro: $1,050 to $1,150 per month
• Zepbound: $1,350 to $1,450 per month

Insurance coverage varies widely. Medicare does not cover GLP-1 medications for weight loss (only for diabetes). Many commercial plans cover diabetes indications but exclude obesity indications or require prior authorization and step therapy.

Compounded versions: Compounded semaglutide and compounded tirzepatide are available through state-licensed compounding pharmacies while the FDA shortage list includes these medications. Pricing for compounded versions typically ranges from $250 to $450 per month depending on dose and provider.

Compounded medications are not FDA-approved and are not identical to brand-name products. They are prepared in response to individual prescriptions and have not undergone the same manufacturing and efficacy review as brand-name drugs.

FormBlends connects patients with licensed providers who can prescribe compounded semaglutide or compounded tirzepatide when clinically appropriate. The cost difference makes treatment accessible to patients without insurance coverage for brand-name medications.

What most articles get wrong about "Mounjaro is stronger"

The most common error in published comparisons is the claim that "Mounjaro is stronger because the dose is higher." You'll see statements like "Mounjaro goes up to 15 mg while Ozempic only goes to 2 mg, so Mounjaro is 7.5 times stronger."

This is wrong. Milligram dose is not a measure of potency across different molecules. Tirzepatide and semaglutide are different peptides with different molecular weights, different receptor binding affinities, and different pharmacokinetics. Comparing them by milligram dose is like comparing ibuprofen and acetaminophen by tablet weight.

The correct comparison is efficacy in clinical trials: how much weight loss, how much A1C reduction, at what cost in side effects. By that measure, tirzepatide produces greater weight loss (roughly 5 to 7 percentage points more total body weight loss over 68 to 72 weeks) but similar glycemic control and similar discontinuation rates.

The second common error is claiming "Mounjaro works faster." Both drugs take 4 to 8 weeks to reach steady-state blood levels and 12 to 20 weeks to show maximum weight-loss velocity. The titration schedules are similar in duration. There is no meaningful difference in time to effect.

The third error is overstating the GIP receptor's role. Some articles claim "GIP is the reason Mounjaro works" or "GLP-1 is for blood sugar, GIP is for weight loss." Both claims are oversimplifications. GLP-1 alone (semaglutide) produces substantial weight loss. GIP adds to that effect, but it's not doing all the work. The two receptors work synergistically.

The decision framework: which medication fits which patient

Use this branching decision tree to identify which medication is the better starting point for a given patient. This is a clinical starting point, not a rigid protocol.

Step 1: Is the primary goal diabetes control or weight loss?

• If diabetes control is primary and weight loss is secondary: either medication works. Mounjaro has a slight edge in A1C reduction (0.4 to 0.6% more). Cost and insurance coverage often decide.
• If weight loss is primary: Mounjaro (tirzepatide) has a clear efficacy advantage in published trials.

Step 2: Does the patient have a history of severe nausea or vomiting on other medications?

• If yes: semaglutide shows lower nausea rates in trials (31.7% vs 44.2% at maximum doses). Start with semaglutide.
• If no: either medication is appropriate.

Step 3: Does the patient have pre-existing GERD or reflux?

• If yes: semaglutide shows lower reflux rates (5.7% vs 9.4%). Consider semaglutide first, or plan aggressive reflux management if choosing tirzepatide.
• If no: either medication is appropriate.

Step 4: What is the insurance coverage situation?

• If insurance covers one but not the other: use the covered medication.
• If neither is covered and patient is paying out of pocket: compounded versions of both are available at similar cost. Choose based on efficacy and side effect profile.
• If both are covered: tirzepatide for weight loss, either for diabetes.

Step 5: Has the patient already tried one and had inadequate response or intolerable side effects?

• If inadequate weight loss on semaglutide after 6+ months at maximum tolerated dose: switch to tirzepatide.
• If intolerable nausea on tirzepatide: switch to semaglutide.
• If intolerable side effects on both: consider dose reduction, slower titration, or alternative treatments.

This framework assumes the patient is appropriate for GLP-1 therapy in the first place (BMI 27+ with comorbidity or BMI 30+, or type 2 diabetes). It does not replace individualized clinical judgment.

[Diagram suggestion: flowchart starting with "Primary goal?" branching to "Diabetes control" and "Weight loss," then further branches for nausea history, GERD history, and insurance coverage, ending in "Start semaglutide" or "Start tirzepatide" boxes.]

FDA approval differences and off-label use

Semaglutide FDA approvals:

• Ozempic: approved 2017 for type 2 diabetes, doses up to 2 mg weekly
• Wegovy: approved 2021 for chronic weight management in adults with BMI 30+ or BMI 27+ with comorbidity
• Rybelsus: approved 2019, oral semaglutide for type 2 diabetes

Tirzepatide FDA approvals:

• Mounjaro: approved 2022 for type 2 diabetes, doses up to 15 mg weekly
• Zepbound: approved 2023 for chronic weight management in adults with BMI 30+ or BMI 27+ with comorbidity

The brand names differ (Ozempic vs Wegovy, Mounjaro vs Zepbound) but the active ingredient is identical. The distinction is regulatory and marketing, not chemical.

Off-label use is common. Ozempic (the diabetes-branded semaglutide) is frequently prescribed off-label for weight loss, especially during Wegovy shortages. Mounjaro is frequently prescribed off-label for weight loss before Zepbound's approval and during Zepbound shortages.

Prescribing a diabetes-branded drug for weight loss is legal and common but may affect insurance coverage. Many insurance plans will not cover a diabetes-branded drug for a non-diabetes indication.

Compounded semaglutide and compounded tirzepatide are not FDA-approved for any indication. They are legal to prescribe and dispense under the Food Drug and Cosmetic Act section 503A while the brand-name versions are on the FDA drug shortage list.

When switching from one to the other makes sense

Switch from semaglutide to tirzepatide when:

• Weight loss has plateaued after 6+ months at semaglutide 2.4 mg (or maximum tolerated dose) and patient wants to lose more weight
• A1C is not at goal after 6+ months on semaglutide 1 to 2 mg
• Insurance coverage changes and tirzepatide becomes covered while semaglutide does not

Switch from tirzepatide to semaglutide when:

• Nausea or vomiting is intolerable despite slower titration and dietary management
• Reflux is severe and persistent despite standard management
• Insurance coverage changes and semaglutide becomes covered while tirzepatide does not

Switching protocol: The standard approach is to start the new medication at its starting dose (semaglutide 0.25 mg or tirzepatide 2.5 mg) one week after the last dose of the old medication. Do not overlap doses. The long half-life (7 days) means there is still drug on board from the previous injection, so starting at a low dose minimizes the risk of stacking side effects.

Some providers use a "bridge dose" approach: if switching from semaglutide 2.4 mg to tirzepatide, start tirzepatide at 5 mg (skipping the 2.5 mg starter dose) because the patient is already adapted to GLP-1 receptor activation. This approach is faster but carries higher nausea risk. The conservative approach is to start at 2.5 mg regardless.

There is no published data on optimal switching protocols. The recommendations above reflect consensus clinical practice.

The FormBlends clinical pattern: who stays on which medication

Across the patient population using compounded GLP-1 medications through FormBlends-connected providers, we see consistent patterns in who stays on semaglutide vs who switches to tirzepatide.

Patients who stay on compounded semaglutide long-term:

• Patients who reach their goal weight on semaglutide and transition to maintenance dosing
• Patients with a history of significant nausea on other medications who tolerate semaglutide well
• Patients who prioritize cost stability (semaglutide has been available compounded longer, with more stable supply)
• Patients with pre-existing GERD who want to minimize reflux risk

Patients who switch from semaglutide to tirzepatide:

• Patients who plateau at 10 to 12% weight loss on semaglutide and want to lose more
• Patients who tolerate semaglutide well and want to try the medication with higher trial efficacy
• Patients whose insurance begins covering Mounjaro or Zepbound but not Ozempic or Wegovy

Patients who start on tirzepatide and stay:

• Patients without significant GI side effect history who want maximum weight-loss efficacy from the start
• Patients who have failed other weight-loss interventions and are looking for the most effective pharmacologic option
• Patients with type 2 diabetes who need both glycemic control and significant weight loss

The pattern is not "everyone switches to tirzepatide." Semaglutide remains the most prescribed GLP-1 medication globally, and many patients reach their goals on it without needing to escalate to a dual agonist. The choice is individual.

What we do not see: patients switching back and forth multiple times. Once a patient finds a medication that works and is tolerable, they tend to stay on it. The switching decision is usually one-time, driven by either inadequate efficacy or intolerable side effects.

FAQ

Is Mounjaro better than Ozempic? Mounjaro (tirzepatide) produces greater weight loss in clinical trials (roughly 5 to 7 percentage points more total body weight loss over 68 to 72 weeks). For diabetes control, both are effective, with Mounjaro showing a modest advantage in A1C reduction. "Better" depends on whether the patient prioritizes maximum weight loss or minimizing nausea and reflux risk.

Can I switch from Ozempic to Mounjaro? Yes. The standard approach is to take your last Ozempic dose, wait one week, then start Mounjaro at the 2.5 mg starting dose. Do not overlap doses. Consult your provider before switching to confirm the timing and dose are appropriate for your situation.

Which has worse side effects, Mounjaro or Ozempic? Ozempic (semaglutide) has higher nausea and vomiting rates in trials. Mounjaro (tirzepatide) has slightly higher reflux rates. Discontinuation rates due to side effects are nearly identical (around 6%). Individual tolerance varies.

Does Mounjaro work faster than Ozempic? No. Both take 4 to 8 weeks to reach steady-state levels and 12 to 20 weeks to show maximum weight-loss velocity. The titration schedules are similar in duration. There is no meaningful difference in time to effect.

Why is Mounjaro more expensive than Ozempic? Brand-name pricing is set by the manufacturer. Mounjaro and Zepbound are newer (approved 2022 and 2023) and have not faced generic competition. Ozempic has been on the market since 2017 but also has no generic. The price difference between Ozempic and Mounjaro is small (roughly $100 per month). Wegovy and Zepbound are priced identically.

Can I take Mounjaro and Ozempic together? No. Both activate the GLP-1 receptor, and taking them together would stack side effects without additional benefit. If one medication is not effective, the approach is to switch to the other or escalate the dose, not to combine them.

Is compounded tirzepatide the same as Mounjaro? No. Compounded tirzepatide is prepared by a state-licensed compounding pharmacy and is not FDA-approved. It contains the same active ingredient (tirzepatide) but has not undergone the same manufacturing and efficacy review as brand-name Mounjaro. Compounded medications are legal and commonly prescribed while brand-name medications are on the FDA shortage list.

Which is better for diabetes, Mounjaro or Ozempic? Both are effective. Mounjaro shows slightly greater A1C reduction in trials (0.4 to 0.6% more on average). The choice often depends on insurance coverage, cost, and patient preference. Many patients reach their A1C goal on either medication.

Which is better for weight loss, Mounjaro or Ozempic? Mounjaro produces greater weight loss in clinical trials. SURMOUNT-1 showed 20.9% total body weight loss on tirzepatide 15 mg vs 14.9% on semaglutide 2.4 mg in STEP 1 over similar durations. Individual results vary, but the population-level difference is consistent.

How much weight can I lose on Mounjaro vs Ozempic? Trial averages: semaglutide 2.4 mg produces 14.9% total body weight loss over 68 weeks. Tirzepatide 15 mg produces 20.9% over 72 weeks. A 250 lb patient would lose roughly 37 lb on semaglutide vs 52 lb on tirzepatide, based on trial means. Individual variation is wide.

Does Mounjaro cause more nausea than Ozempic? No. Semaglutide shows higher nausea rates in trials (44.2% vs 31.7% at maximum doses). Tirzepatide shows slightly higher reflux rates. The GI side effect profiles overlap but are not identical.

Can I use Mounjaro if Ozempic didn't work for me? Yes. If you reached a weight-loss plateau on semaglutide or did not achieve adequate glycemic control, switching to tirzepatide is a reasonable next step. Consult your provider to confirm the switch is appropriate and to plan the transition.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2): a randomised trial. Lancet. 2021.
5. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
6. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
7. Holst JJ et al. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007.
8. Gasbjerg LS et al. Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals. Diabetes. 2019.
9. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Diabetes Obesity and Metabolism. 2018.
10. Frias JP et al. The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metabolism. 2017.
11. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021.
12. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
13. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021.
14. American Diabetes Association. Standards of Medical Care in Diabetes 2026. Diabetes Care. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, Wegovy, and Rybelsus are registered trademarks of Eli Lilly and Company and Novo Nordisk respectively. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.